Array refocuses, cuts 20% of staff; loses Amgen partnership
This article was originally published in Scrip
Array BioPharma CEO Ron Squarer said it would be "unfortunate" for discontinuation of a non-core partnership with Amgen and an unrelated 20% staff reduction to distract from late-stage progress in the Boulder, Colorado-based company's clinical development pipeline.
You may also be interested in...
Oncology R&D head Axel Hoos spoke with Scrip about data at ASCO and the company’s strategy in immuno-oncology, cancer epigenetics, cell and gene therapy and synthetic lethality.
Private Company Edition: Arvelle, insitro, AbCellera and the University of Michigan have something in common – they each attracted more than $100m in venture capital investment.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.